Efficacy and safety of switching to ezetimibe 10 mg/rosuvastatin 2.5 mg in Korean patients with type 2 diabetes mellitus and dyslipidaemia: A multicentre, prospective study ( <scp>EROICA</scp> study)
Switching to ezetimibe 10 mg/rosuvastatin 2.5 mg achieved substantial LDL-C reductions, high goal attainment, excellent adherence, and good tolerability in Korean T2DM patients with dyslipidaemia.
Authors
- Min Kyong Moon (ORCID: https://orcid.org/0000-0002-5460-2846)
- Sungrae Kim (ORCID: https://orcid.org/0000-0001-6417-8412)
- Cheol‐Young Park (ORCID: https://orcid.org/0000-0002-9415-9965)
- Sangmo Hong (ORCID: https://orcid.org/0000-0002-8535-0565)
- Eun Seok Kang (ORCID: https://orcid.org/0000-0002-0364-4675)
- Ji‐Oh Mok (ORCID: https://orcid.org/0000-0003-4882-1206)
- Jung H. Park
- Chang Beom Lee (ORCID: https://orcid.org/0000-0003-4891-834X)
- Ki‐Young Lee (ORCID: https://orcid.org/0000-0003-4893-3195)
- Won Jung Kim (ORCID: https://orcid.org/0000-0001-9208-6101)
- Jae Taek Kim
Institutions
- Ulsan College (KR)
- Seoul National University (KR)
- Yonsei University (KR)
- Soonchunhyang University (KR)
- Soonchunhyang University Hospital Seoul (KR)
- New Generation University College (ET)
- University of Ulsan (KR)
- SNUH SMG-SNU Boramae Medical Center (KR)
- Kangbuk Samsung Hospital (KR)
- The Catholic University of Korea Bucheon St. Mary's Hospital (KR)
- Gangneung Asan Hospital (KR)
- Deleted Institution
- Hanyang University (KR)
- Bucheon University (KR)
- Chung-Ang University (KR)
- Catholic University of Korea (KR)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2025-11-05
- DOI
- https://doi.org/10.1111/dom.70258
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 0.00